Immunovia publ AB
The answer first
Does Immunovia beat the market?
No, Immunovia has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 0% of Nordic stocks
- Quality15
- Value7
- Trend1
No. 194 of 195 in healthcare
Max for seven days
Follow Immunovia with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Immunovia
Your first answer is free, no account needed.
Do you own Immunovia, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Immunovia and a few more. Free, no card.
Super Stock+44.6%In short
- Immunovia has fallen 88.0% over the past year, including dividends.
- Overall, Immunovia ranks better than 0% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 99.1%. The price is 100.0% below its peak now.
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 0% of Nordic stocks.
No. 194 of 195 in healthcare
Low Weaker accounts than most: low profitability, high debt or uneven results.
No. 177 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.89
- Asset turnoverSales divided by everything the company owns0.06
- Return on equityProfit divided by equity−373.7%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 149 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity3.3
- P/SPrice divided by sales11.2
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 193 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−78.4%
- 6 months−84.3%
- 9 months−80.6%
- 12 months−88.0%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Immunovia
3 funds we follow own Immunovia. The share is how much of the fund the stock makes up.
- Sweden3
From the funds' latest known holdings.
About Immunovia
Immunovia publ AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 19 employees.
Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.


See the full analysis of Immunovia.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card